TY - JOUR T1 - Combined and alone apoptotic effects of Ankaferd hemostat and silver nanoparticles on chronic myeloid leukemia (CML) cell line K562 TT - Ankaferd kanama durdurucu ve gümüş nanopartiküllerin kronik miyeloid lösemi (KML) hücre hattı K562 üzerindeki kombine ve tek başına apoptotik etkileri AU - Ünver Koluman, Başak AU - Seçme, Mücahit AU - Dodurga, Yavuz PY - 2025 DA - April Y2 - 2025 DO - 10.31362/patd.1583891 JF - Pamukkale Medical Journal JO - Pam Tıp Derg PB - Pamukkale University WT - DergiPark SN - 1308-0865 SP - 330 EP - 338 VL - 18 IS - 2 LA - en AB - Purpose: This study aimed to evaluate the effects of Ankaferd hemostat (ABS; Ankaferd Blood Stopper®) and silver nanoparticles (AgNPs), alone or in combination, on human chronic myeloid leukemia (CML) cells.Materials and methods: The cytotoxicity of ABS and AgNPs on K562 CML cells was assessed using the XTT assay, measuring cell viability over time and across different doses. The half maximal inhibitory concentration (IC50) was determined at 72 hours. Apoptosis-related gene expression was analyzed by Real-Time PCR, and oxidative stress was assessed by total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI).Results: AgNPs reduced cell viability at higher doses, with the IC50 for 40 nm AgNPs being 107.8854 ppm at 72 hours. ABS reduced cell viability by 75% even at maximum dose. Significant changes (p<0.05) were observed in bcl-2, caspase-8 and CDK4 in the AgNPs group. In the ABS group, bcl-2, and CDK4 expressions were significantly elevated. The combined treatment increased caspase-8 and caspase-9 expressions, promoting apoptosis. No significant differences were found in TAS-TOS, but all groups showed higher oxidant activity compared to the control, with the combination group exhibiting the highest antioxidant effect.Conclusion: ABS, a herbal treatment with minimal side effects, and AgNPs, a promising therapeutic agent, both showed potential in inhibiting tumor cells. Their combination enhanced apoptotic effects, warranting further investigation. KW - Chronic myeloid leukemia KW - Ankaferd hemostat KW - silver nanoparticles KW - apoptosis KW - oxidative stress N2 - Amaç: Bu çalışma, Ankaferd hemostat (ABS; Ankaferd Blood Stopper®) ve gümüş nanopartiküllerinin (AgNP'ler), tek başına veya kombinasyon halinde, insan kronik miyeloid lösemi (KML) hücreleri üzerindeki etkilerini değerlendirmeyi amaçlamıştır.Gereç ve yöntem: ABS ve AgNP'lerin K562 KML hücreleri üzerindeki sitotoksik etkisi, XTT testi ile değerlendirilmiş ve farklı dozlar ve zaman dilimlerinde hücre canlılığı ölçülmüştür. Yarı maksimal inhibitör konsantrasyonu (IC50) değeri 72 saat sonunda belirlenmiştir. Apoptoz ile ilişkili gen ekspresyonları Real-Time PCR ile analiz edilmiş, oksidatif stres ise total antioksidan durumu (TAS), total oksidan durumu (TOS) ve oksidatif stres indeksi (OSI) kullanılarak değerlendirilmiştir.Bulgular: AgNP'ler, doz arttıkça hücre canlılığını düşürmüş ve 40 nm AgNP'ler için IC50 değeri 72 saat sonunda 107.8854 ppm olarak bulunmuştur. ABS, maksimum dozda bile hücre canlılığını %75 oranında düşürmüştür. AgNP grubunda bcl-2, kaspaz-8 ve CDK4 ekspresyonlarında anlamlı değişiklikler (p<0,05) gözlemlenmiştir. ABS grubunda ise bcl-2 ve CDK4 ekspresyonları anlamlı şekilde artmıştır. Kombine tedavi, kaspaz-8 ve kaspaz-9 ekspresyonlarını artırarak apoptozu teşvik etmiştir. TAS-TOS arasında anlamlı bir fark bulunmamış, ancak tüm gruplarda kontrol grubuna kıyasla daha yüksek oksidan aktivite gözlemlenmiş, kombinasyon grubunda ise en yüksek antioksidan etki saptanmıştır.Sonuç: Yan etkileri minimal olan bir bitkisel tedavi olan ABS ve umut verici bir tedavi ajanı olan AgNP'ler, tümör hücrelerini inhibe etme potansiyeli göstermiştir. Kombinasyonları apoptoz üzerindeki etkilerini artırmış ve daha fazla araştırma yapılmasını gerektirmiştir. CR - 1. Eden RE, Coviello JM. Chronic Myelogenous Leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531459/. Accessed January 16, 2023 CR - 2. Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336-1343. doi:10.1038/leu.2015.73 CR - 3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30. doi:10.3322/caac.21387 CR - 4. Snyder D. CML Chapter. Cancer Treat Res. 2021;181:97-114. doi:10.1007/978-3-030-78311-2_6 CR - 5. Schoepf AM, Gust R. Novel strategies to eradicate resistant cells in chronic myeloid leukemia. Future Med Chem. 2020;12(23):2089-2092. doi:10.4155/fmc-2020-0278 CR - 6. Çiftçiler R, Haznedaroglu İC. Ankaferd hemostat: from molecules to medicine. Turk J Med Sci. 2020;50(SI-2):1739-1750. doi:10.3906/sag-1908-161 CR - 7. Koçak E, Çelebier M, Haznedaroglu IC, Altınöz S. Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach. Biomed Res Int. 2019;2019:5268031. doi:10.1155/2019/5268031 CR - 8. Koluman A, Akar N, Malkan UY, Haznedaroglu IC. Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids. Biomed Res Int. 2016;2016:8957820. doi:10.1155/2016/8957820 CR - 9. Islam MA, Jacob MV, Antunes E. A critical review on silver nanoparticles: From synthesis and applications to its mitigation through low-cost adsorption by biochar. J Environ Manage. 2021;281:111918. doi:10.1016/j.jenvman.2020.111918 CR - 10. Bruna T, Maldonado Bravo F, Jara P, Caro N. Silver Nanoparticles and Their Antibacterial Applications. Int J Mol Sci. 2021;22(13):7202. doi:10.3390/ijms22137202 CR - 11. Zhao Q, Sun XY, Wu B, et al. Construction of biomimetic silver nanoparticles in the treatment of lymphoma. Mater Sci Eng C Mater Biol Appl. 2021;119:111648. doi:10.1016/j.msec.2020.111648 CR - 12. Dodurga Y, Seçme M, Eroğlu C, et al. Investigation of the effects of a sulfite molecule on human neuroblastoma cells via a novel oncogene URG4/URGCP. Life Sci. 2015;143;27-34. doi:10.1016/j.lfs.2015.10.005 CR - 13. Alur İ, Dodurga Y, Seçme M, et al. Anti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells. Gene. 2016;585(2):241-246. doi:10.1016/j.gene.2016.03.044 CR - 14. Bukeirat M, Sarkar SN, Hu H, Quintana DD, Simpkins JW, Ren X. MiR-34a regulates blood-brain barrier permeability and mitochondrial function by targeting cytochrome c. J Cereb Blood Flow Metab. 2016;36(2):387-392. doi:10.1177/0271678X15606147 CR - 15. Pérez MJ, Ponce DP, Aranguiz A, Behrens MI, Quintanilla RA. Mitochondrial permeability transition pore contributes to mitochondrial dysfunction in fibroblasts of patients with sporadic Alzheimer's disease. Redox Biol. 2018;19:290-300. doi:10.1016/j.redox.2018.09.001 CR - 16. Wu H, Lin J, Liu P, et al. Reactive oxygen species acts as executor in radiation enhancement and autophagy inducing by AgNPs. Biomaterials. 2016;101:1-9. doi:10.1016/j.biomaterials.2016.05.031 CR - 17. Nayak D, Kumari M, Rajachandar S, Ashe S, Thathapudi NC, Nayak B. Biofilm Impeding AgNPs Target Skin Carcinoma by Inducing Mitochondrial Membrane Depolarization Mediated through ROS Production. ACS Appl Mater Interfaces. 2016;8(42):28538-28553. doi:10.1021/acsami.6b11391 CR - 18. Albayrak M, Celebi H, Albayrak A, et al. Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia. Eurasian J Med. 2011;43(3):192-195. doi:10.5152/eajm.2011.42 CR - 19. Mumcuoglu M, Akin DF, Ezer U, Akar N. Ankaferd Blood Stopper induces apoptosis and regulates PAR1 and EPCR expression in human leukemia cells. Egypt J Med Hum Gen. 2015;16(1):19-27. doi:10.1016/j.ejmhg.2014.10.001 CR - 20. Malkan UY, Haznedaroglu IC. Antineoplastic Effects of Ankaferd Hemostat. Biomed Res Int. 2022;2022:2665903. doi:10.1155/2022/2665903 CR - 21. Akalın İ, Okur FV, Haznedaroğlu İC, et al. Acute in Vitro effects of ABS (Ankaferd Hemostat) on the Lymphoid Neoplastic Cells (B-CLL and RAJI Tumor Cell Lines). UHOD. 2014;24(4):253-259. doi:10.4999/uhod.13026 CR - 22. Guo D, Zhao Y, Zhang Y, et al. The cellular uptake and cytotoxic effect of silver nanoparticles on chronic myeloid leukemia cells. J Biomed Nanotechnol. 2014;10(4):669-678. doi:10.1166/jbn.2014.1625 CR - 23. Zhou Y, Wang X. Study on synergistic effect of new functionalized Ag nanoparticles for intracellular drug uptake in cancer cells. Nano Biomed Eng. 2010;2(4):208-213. doi:10.5101/nbe.v2i4.p208-213 UR - https://doi.org/10.31362/patd.1583891 L1 - https://dergipark.org.tr/en/download/article-file/4360342 ER -